Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection
Latest Information Update: 12 May 2025
At a glance
- Drugs Cytomegalovirus immune globulin (Primary) ; Valganciclovir
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHIELD
Most Recent Events
- 12 May 2025 New trial record